This Article Abstract Full Text (PDF) All Versions of this Article: 108/20/2498    most recent 01.CIR.0000097119.57756.EFv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lucas, A. D. Articles by Greaves, D. R. Search for Related Content PubMed PubMed Citation Articles by Lucas, A. D. Articles by Greaves, D. R. Related Collections Pathophysiology Mechanism of atherosclerosis/growth factors

(Circulation. 2003;108:2498.)
© 2003 American Heart Association, Inc.

Basic Science Reports

Smooth Muscle Cells in Human Atherosclerotic Plaques Express the Fractalkine Receptor CX₃CR1 and Undergo Chemotaxis to the CX₃C Chemokine Fractalkine (CX₃CL1)

Andrew D. Lucas, PhD^*; Christina Bursill, PhD^*; Tomasz J. Guzik, MD, PhD; Jerzy Sadowski, MD, PhD; Keith M. Channon, MD; David R. Greaves, PhD

From the Sir William Dunn School of Pathology, University of Oxford (A.D.L., C.B., D.R.G.), and Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford (C.B., T.J.G., K.M.C.), UK; and the Department of Internal Medicine, Jagiellonian University School of Medicine, J. Dietl Hospital, Kraków, Poland (T.J.G., J.S.).

Correspondence to David R. Greaves, Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK. E-mail david.greaves{at}path.ox.ac.uk

Received November 14, 2002; de novo received June 11, 2003; revision received August 14, 2003; accepted August 19, 2003.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Chemokines are important mediators of inflammatory cell recruitment that play a significant role in atherosclerosis. Fractalkine (CX₃CL1) is an unusual membrane-bound chemokine that mediates chemotaxis through the CX₃CR1 receptor. Recently, functional polymorphisms in the human CX3CR1 gene have been described that are associated with coronary artery disease.

Methods and Results— We investigated the expression of the CX₃C chemokine fractalkine and its receptor CX₃CR1 in human coronary artery plaques by immunocytometry. We show that a subset of mononuclear cells expresses high levels of fractalkine in human coronary atherosclerotic plaques and that smooth muscle cells within the neointima express the fractalkine receptor CX₃CR1. There is a positive correlation between the number of fractalkine-expressing cells and the number of CX₃CR1-positive cells in human atherosclerotic plaques (r=0.70, n=15 plaques). Furthermore, we demonstrate that cultured vascular smooth muscle cells express the CX₃CR1 receptor and undergo chemotaxis to fractalkine that can be inhibited by G protein inactivation by pertussis toxin.

Conclusions— These results suggest that in human atherosclerosis, fractalkine, rather than mediating inflammatory cell recruitment, can act as a mediator of smooth muscle cell migration.

Key Words: chemokines • atherosclerosis • macrophages • muscle, smooth • remodeling

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Local and systemic inflammation play critical roles in the development of atherosclerosis.^1–4 Monocytes that adhere to inflamed endothelium are recruited into the subendothelial space, where they differentiate into macrophages. Recruited macrophages endocytose modified forms of LDL via scavenger receptors to form foam cells, which are the predominant cell type present in fatty streak lesions.⁵ These lesions develop into fibrofatty plaques, which contain large numbers of macrophages and CD4+ T cells and show evidence of smooth muscle cell (SMC) migration and proliferation.^5–7

Chemokines are a superfamily of chemoattractant cytokines that play an essential role in leukocyte recruitment in acute and chronic inflammation.^5,8–10 A key role for the CC chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2) has been demonstrated in murine models of atherogenesis. LDLR^-/- and apoE^-/- mice with deletion of either the MCP-1 or the CCR2 gene exhibit reduced atherosclerosis.^5,11,12 Recently, MCP-1 has been demonstrated to play an important role in other forms of vascular remodeling, including restenosis.^5,13,14 MCP-1 is expressed by a range of cell types in human atherosclerotic plaques, including macrophages and SMCs.¹⁵ Other CC chemokines that are expressed in human atherosclerotic plaques include eotaxin (CCL11), macrophage-derived chemokine (MDC/CCL22), and thymus- and activation-regulated chemokine (TARC/CCL17).^16,17 A potential role for CXC chemokines in the development of atherosclerotic lesions has also been demonstrated in gene knockout animals.^16,18,19

Fractalkine (CX₃CL1) is synthesized as a membrane-bound molecule with the chemokine motif attached to a long mucin stalk.²⁰ It is expressed by a range of cell types in vivo, including neurons,²¹ epithelial cells,²² and macrophages.¹⁷ The receptor for fractalkine, CX₃CR1, is a G protein-coupled receptor (GPCR) with 7 transmembrane (TM7)-spanning regions.²³ The CX₃CR1 receptor is able to mediate tight adhesion of cells to immobilized forms of fractalkine under flow conditions in vitro.^24,25 Fractalkine gene knockout mice have no obvious defects in leukocyte trafficking but are less susceptible to cerebral ischemia-reperfusion injury.^26,27 Further evidence for a possible role of fractalkine in cardiovascular disease has come from recent observations in human subjects suggesting that a single amino acid polymorphism at position 249 of the CX₃CR1 receptor is an independent risk factor for coronary artery disease^28,29 (reviewed by Alexander³⁰). However, the biological rationale for these observations remains unclear

Accordingly, we investigated the presence of fractalkine and its cognate receptor, CX₃CR1, in human coronary artery atherosclerotic plaques. We show that fractalkine expression is principally by mononuclear cells, whereas the fractalkine receptor CX₃CR1 is expressed by intimal SMCs. Furthermore, we demonstrate that human SMCs can undergo chemotaxis to fractalkine in vitro. These results lead us to propose fractalkine as a newly identified mediator of SMC migration in human coronary atherosclerosis.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Human Tissues
Sections of right and left coronary arteries were taken from hearts removed from transplant recipients (9 men, 1 woman; mean age, 51 years) with appropriate local ethical approval and written informed consent. For more details see Table 1.

View this table: [in this window] [in a new window]   TABLE 1. Coronary Artery Samples Used in This Study

Human Primary Cells and Cell Lines
Human coronary artery SMCs were prepared from a 21-year-old male donor (TCS CellWorks). Cells were typically passaged 2 times before use. For immunohistochemistry experiments, 1x10⁴ cells were seeded into glass chamber slides (Nunc) and grown until confluent. For Western blot analysis, cells (5x10⁵) were seeded into 6-well cluster dishes (Costar) and grown until confluent. Where indicated, cells were grown in the presence of tumor necrosis factor- (10 ng/mL) or interferon- (500 U/mL, PeproTech) for 24 hours before analysis. The human SMC line HCM-601EB (a kind gift of Professor Martin Bennett, Addenbrooke’s Hospital, Cambridge, UK) has been described previously.³¹ Transfected CHO-K1 and HEK 293 cells were grown in RPMI 1640 cell culture media supplemented with 10% FCS, glutamine (2 mmol/L), and penicillin/streptomycin (5 IU/mL, 50 µg/mL, respectively; InVitrogen Lifetech).

Chemotaxis Assays
Cell migration was assessed by use of transwell membranes (ChemoTX, 6-mm diameter, 8-µm pore size) as described previously.³² Cells were harvested, placed on transwell membranes, and allowed to migrate toward increasing concentrations of fractalkine or platelet-derived growth factor (PDGF)-AB. Migrated cells on the underside of membranes were fixed (paraformaldehyde-sucrose) and stained with Topro blue. Migration was quantified as total pixel count of blue cells under the confocal microscope (scans performed in triplicate, 3 scans/membrane). Signal transduction via G protein-coupled receptors was blocked by preincubating cells with pertussis toxin (PTX, 250 ng/mL, Sigma-Aldrich) for 2 hours before chemotaxis.

Western Blotting
The expression of CX₃CR1 and fractalkine by primary human coronary artery cells was evaluated by Western blotting, as described previously.²² Detergent lysates derived from human peripheral blood mononuclear cells (PBMCs) or CD14+ monocytes were used as a positive control.

Immunohistochemistry
The following primary antibodies were used: rat anti-human CX₃CR1 (isotype IgG2b, clone 2A9-1, MBL); rabbit anti-human CX₃CR1 N-terminal peptide (ProSci Inc); goat anti-fractalkine chemokine domain (R&D Systems); mouse anti-hemagglutinin epitope (YPYDVPDYA) (isotype IgG1, clone 16B12, Covance); mouse anti-human CD14 (isotype IgG2a, clone TÜK4, Dako AS), mouse anti-human CD3 (isotype IgG1, clone UCHT1, Dako), and mouse anti-human CD68 (isotype IgG1, Clone EBM11, Dako). All antibodies were diluted in PBS containing 1% BSA and 0.2% Triton X-100, and sections were incubated with primary antibodies overnight at 4°C. In cases in which a red label was required for visualization, samples were incubated with anti-species-specific IgG conjugated to Alexa Fluor 568 (Molecular Probes) for 1 hour at 4°C. In cases in which a green label was required for visualization, samples were incubated with anti-species-specific IgG conjugated to biotin (Dako) for 1 hour at 4°C. Finally a streptavidin-fluorescein isothiocyanate (FITC) reagent (Amersham) was applied for 30 minutes at 4°C. Double immunofluorescent labeling involved sequential single-labeling procedures, with all incubations at 4°C. Immunohistochemical detection of single antigens was performed as described previously.^17,22

Validation of Anti-CX₃CR1 Antisera
To verify the specificity of a range of anti-CX₃CR1 reagents, we transfected HEK-293 cells with an expression vector encoding CX₃CR1 tagged at the C-terminus with the influenza hemagglutinin (HA) epitope tag. FACS analysis of transfected cells with mouse anti-hemagglutinin monoclonal antibody detected a strongly positive population of transfected cells, and a similar population was revealed by use of a rat anti-human CX₃CR1 monoclonal antibody. Two commercial rabbit polyclonal reagents varied in their ability to detect CX₃CR1 antigens in FACS and immunofluorescence, with the ProScience anti-N-terminal peptide reagent giving specific staining of CX₃CR1-transfected CHO cells (data not shown).

	Results

Top Abstract Introduction Methods Results Discussion References

 
Expression of Fractalkine and CX₃CR1 in Human Coronary Atherosclerosis
To address whether fractalkine could be detected in association with coronary artery disease, freshly isolated human coronary artery segments from heart transplant recipients were examined by immunohistochemistry. We examined 19 separate arteries sampled from 10 patients (Table 1). Most but not all arteries showed intimal areas characterized by an infiltrate of mononuclear cells, clearly counterstained with hematoxylin in the goat IgG isotype control experiment (Figure 1A). A proportion of the infiltrating mononuclear cells within the intima stained strongly positive for fractalkine (Figure 1B). Consistent with our previous studies on carotid and femoral arteries,²⁰ we did not detect fractalkine immunostaining of luminal endothelial cells in any of the sections studied. Indeed, occasional fractalkine-positive mononuclear cells were seen adhering to the unstained luminal endothelium that showed clear staining for von Willebrand factor in adjacent sections (data not shown).

View larger version (86K): [in this window] [in a new window]   Figure 1. Fractalkine expression in human coronary arteries. Adjacent frozen sections (8 to 10 µm) of coronary artery HCA007L were analyzed by immunohistochemistry. Sections were counterstained with hematoxylin and examined by light microscopy. A, Preimmune goat serum; B, goat anti-fractalkine polyclonal reagent. Similar results were obtained with 17 of 19 coronary artery samples.

Next, we performed double immunofluorescence labeling to identify the fractalkine-positive cells within coronary artery sections (red-staining cells in Figure 2, A–E, summarized in Table 2). Infiltrating CD3-positive T cells (stained green in Figure 2A) were present in most lesions examined (9 of 10 plaques), whereas CD14 monocytes (green in Figure 2C) were detected in 4 of 6 lesions examined and were only rarely double positive for fractalkine expression. These CD14 fractalkine double-positive cells were located just beneath the luminal endothelium, consistent with their being recently transmigrated monocytes (Figure 2C). A more substantial proportion of the fractalkine-positive cells double-stained for the CD68 antigen (stained yellow in Figure 2B; CD68 single-positive cells are green). In lesions containing large CD68-positive cells with the appearance of foam cells, there was a lack of double labeling with fractalkine (data not shown). Smooth muscle actin-positive cells were present within the intima (stained green in Figure 2D), and in 7 of 14 lesions examined, we were able to detect some SMCs that expressed fractalkine.

View larger version (39K): [in this window] [in a new window]   Figure 2. Double immunofluorescence analysis of fractalkine- and CX3CR1-expressing cells in human atherosclerosis. A–E, Serial sections from a single representative infiltrated atherosclerotic plaque (HCA007L) double-immunofluorescently labeled with goat anti-human fractalkine (red). A, Anti-CD3 positive T cells (green); B, anti-CD68-positive macrophages (green); C, anti-CD14-positive monocytes (green); D, anti--actin-positive SMCs (green); and E, rat anti-CX3CR1-stained cells (green). F, Staining of same plaque with anti-CX3CR1 (green) and anti--actin (red) revealed that most CX3CR1-positive cells are also positive for SMC actin.

View this table: [in this window] [in a new window]   TABLE 2. Summary of Coronary Artery Sample Double-Staining Experiments

Thus, cells expressing fractalkine in human coronary artery plaques included CD68-positive macrophages, CD14-positive monocytes, some SMCs, and a significant population of mononuclear cells that were negative for these markers but not endothelial cells.

To determine the relationships between cells expressing fractalkine and those expressing the fractalkine receptor in human coronary artery plaques, we performed double immunofluorescent staining for the fractalkine receptor CX₃CR1. Strikingly, fractalkine receptor-positive cells with the characteristics of SMCs (green in Figure 2E) were present adjacent to fractalkine-positive cells (red in Figure 2E) within the intimal region in 16 of the 19 coronary lesions examined, and in 8 of 19 lesions examined, we detected some cells that were positive for both fractalkine and CX3CR1. Confirmation of the CX₃CR1-positive cells as SMCs was obtained by double staining with an anti-smooth muscle actin antibody (yellow cells in Figure 2F). When the numbers of fractalkine- and SMC actin-positive cells were determined, no relationship could be demonstrated (Figure 3A; r=0.1, P=NS). However, there was a strong positive correlation between the numbers of fractalkine-positive and fractalkine receptor-positive cells within lesions (Figure 3B; r=0.70, P<0.01).

View larger version (14K): [in this window] [in a new window]   Figure 3. Quantitative image analysis of fractalkine- and CX3CR1-positive cells in human atherosclerosis. Human coronary arteries were double-labeled for fractalkine and its receptor, CX3CR1. Representative views of human artery sections were electronically captured by CCD camera, and cells positive for either label were counted within a standardized area (1.5x104 µm2) that contained at least 1 fractalkine-positive cell in lesions double-labeled with CX3CR1 or smooth muscle actin (SMA). A, Numbers of fractalkine-positive and SMA-positive cells are shown as an xy plot, and correlation between co-incidence of both markers was calculated. B, Numbers of fractalkine-positive and CX3CR1-positive cells were plotted as an xy plot, and correlation between co-incidence of both markers was calculated. Distinct symbols represent data points from individual arteries.

Primary Human SMCs Express the Fractalkine Receptor CX₃CR1 and Undergo Chemotaxis to Fractalkine
To further investigate expression of the fractalkine receptor CX₃CR1 by SMCs, we cultured primary human coronary artery SMCs to a 60% to 70% confluence on glass chamber slides. Cells were fixed and stained for CX₃CR1 and smooth muscle actin expression. We detected strong, punctate cellular staining for the fractalkine receptor CX₃CR1 relative to rat IgG2b isotype control antibody (Figure 4A). This staining was both perinuclear and clearly distributed on the plasma membrane (Figure 4A, arrow). Western blotting of primary human PBMCs, CD14 positively selected monocytes, and primary human coronary artery SMC lysates for CX₃CR1 revealed a band of 45 kDa in all 3 cell preparations (Figure 4B). Human primary SMC lysates but not monocyte lysates were positive for smooth muscle actin expression (Figure 4C). These observations confirm that primary human SMCs express the fractalkine receptor CX₃CR1.

View larger version (49K): [in this window] [in a new window]   Figure 4. Human SMCs express fractalkine receptor CX3CR1. Human primary coronary artery SMCs grown in normal growth media in glass chamber slides were fixed with 4% paraformaldehyde and labeled with following reagents. A, Inset, Rat IgG2a isotype control followed by anti-rat IgG-FITC and mouse anti-human smooth muscle actin followed by anti-mouse IgG-Cy3. Main panel, rat anti-human CX3CR1 followed by anti-rat IgG-FITC and mouse anti-human SMA followed by anti-mouse IgG-Cy3. Arrow highlights punctate CX3CR1-FITC labeling on surface of a cell extension. B, Western blot analysis of human PBMCs, purified CD14+ human monocytes, and primary coronary artery SMCs probing for CX3CR1 expression. Cell lysates were separated by 8% polyacrylamide-SDS gel electrophoresis, transferred to nitrocellulose membranes, and probed for CX3CR1 expression with a polyclonal rabbit anti-CX3CR1 NT reagent (ProScience), which detects a specific band of 45 kDa. C, Monocyte and SMC lysates were probed for smooth muscle actin expression.

To investigate the responsiveness of human SMCs to recombinant human fractalkine, we used the human SMC line HCM-601EB and primary SMCs in chemotaxis assays in modified Boyden chambers. HCM-601EB cells migrated in response to both recombinant fractalkine (Figure 5A) and PDGF-AB (Figure 5B), showing a characteristic "bell-shaped" curve typical of chemokine migration assays. The maximal migration occurred to 25 nmol/L fractalkine and 4 nmol/L PDGF-AB. As a further test of specificity, we preincubated HCM-601EB cells with PTX (250 ng/mL), an inhibitor of G protein-coupled receptor signaling. As expected, the migratory response to fractalkine was blocked by PTX (Figure 5C), because the fractalkine receptor is a G_i-coupled receptor. In contrast, the response to PDGF, mediated by the tyrosine kinase PDGF receptor, was not affected (Fig 5D). Importantly, we demonstrated that primary human coronary artery SMCs undergo chemotaxis to fractalkine (Figure 5E) and that this chemotaxis is sensitive to PTX inhibition (Figure 5F).

View larger version (23K): [in this window] [in a new window]   Figure 5. Fractalkine mediates SMC chemotaxis. In transwell membranes, human HCM-601EB SMCs were exposed to a range of increasing doses of (A) recombinant human fractalkine (0 to 80 nmol/L) or (B) recombinant PDGF-AB (0 to 24 nmol/L). Migrated cells were fixed and stained on underside of transwell membranes. Migration was quantified as total pixel count of blue fluorescent nuclei imaged by confocal microscopy (triplicate experiments, 3 scans/membrane). C, HCM-601EB cells were allowed to migrate toward buffer alone (blank), fractalkine (Frac) (25 nmol/L) with or without preincubation with PTX (250 ng/mL). By ANOVA, P<0.05 between Blank vs Fractalkine and Fractalkine vs PTX. D, HCM-601EB cells were allowed to migrate toward buffer alone (blank) or PDGF (4 nmol/L) with or without preincubation with PTX (250 ng/mL). P<0.05 between blank vs PDGF and blank vs PDGF+PTX. E, Human coronary artery primary SMCs were allowed to migrate toward increasing concentrations of recombinant human fractalkine (0 to 80 nmol/L). F, Human primary SMCs were allowed to migrate toward buffer alone (blank) or recombinant human fractalkine (40 nmol/L) with or without preincubation with PTX (250 ng/mL). P<0.001 between blank vs fractalkine and fractalkine±PTX.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
We have undertaken a detailed analysis of the expression pattern of the CX₃C chemokine fractalkine and its receptor, CX₃CR1, in human coronary atherosclerosis. Fractalkine is expressed at a high level by a subset of inflammatory cells but not by endothelial cells. The number of fractalkine-expressing cells in the intima is directly correlated with the presence of CX₃CR1⁺ cells, most of which are SMCs. Furthermore, we have demonstrated that primary human SMCs express the CX₃CR1 receptor and can undergo specific CX₃CR1-mediated chemotaxis to fractalkine in vitro. Our results suggest that fractalkine, rather than acting as a proinflammatory cytokine in human atherosclerosis, may play an important role in vascular remodeling through the recruitment of SMCs into the atherosclerotic plaque.

In vitro SMCs³³ and cultured endothelial cells²⁰ treated with a range of inflammatory mediators express fractalkine mRNA and protein. However, we saw no evidence of endothelial expression of fractalkine in human coronary atherosclerosis (Figure 1). Rather, infiltrating mononuclear cells present in the intima of human coronary artery atherosclerotic plaques express high levels of fractalkine. These cells are primarily CD14- and CD68-negative and may represent recruited monocytes that are in the process of differentiation. We used validated anti-CX₃CR1 antibodies to identify fractalkine receptor-expressing cells in human atherosclerosis. Quantitative image analysis shows a positive correlation between the presence of CX₃CR1⁺ cells in the neointima and fractalkine-expressing mononuclear cells (Figure 3B). The majority of these CX₃CR1⁺ cells were shown by double immunofluorescence to be SMCs. Taken together with the chemotaxis data presented in Figure 5, our observations strongly suggest that rather than playing a role in continuing inflammatory cell recruitment, fractalkine expression within human atherosclerotic plaques may be acting to recruit SMCs. By recruiting cells capable of synthesizing substantial amounts of extracellular matrix, fractalkine expression may favor the development of stable atherosclerotic lesions rather than macrophage-rich vulnerable plaques. It will be interesting to determine whether developing atherosclerotic plaques that express high levels of fractalkine within the neointima progress to stable plaques with high numbers of SMCs and fibrous caps. In a recent article, Chandrasekar et al³⁴ reported CX₃CR1-dependent proliferation of primary rat aortic SMCs in response to fractalkine. However, an overenthusiastic recruitment of SMCs into a developing plaque followed by fractalkine-driven SMC proliferation could result in SMC-dominated intimal hyperplasia.

Recently, coding region polymorphisms, V249I and T280M, have been identified in the human CX3CR1 gene and appear to be associated with reduced risk of developing coronary artery disease.^28,29,35 PBMCs prepared from human donors with different CX3CR1 genotypes exhibit differences in the number of fractalkine-binding sites per cell, and cells transfected with variant receptor show impaired ligand-dependent cell adhesion.³⁵ However, the biological rationale for an association between genetic variation in CX₃CR1 and coronary artery disease has remained unclear. Our study now provides novel data on CX₃CR1 expression in human coronary atherosclerosis. Our observations suggest that a potential mechanistic link between CX3CR1 gene polymorphisms in human populations and the development of coronary artery disease may be exerted not only at the level of monocyte recruitment but also at the level of atherosclerotic plaque stability through modulation of SMC recruitment. The only other identified high-affinity receptor for fractalkine is encoded by the US28 open reading frame of human cytomegalovirus, and evidence has been presented for a link between cytomegalovirus infection and SMC proliferation in atherosclerosis.^36,37

More than 40 different human chemokines have been described, and the majority of CC chemokines have been shown to be potent mediators of either monocyte or T-cell chemotaxis.¹⁰ Indeed, CX3CR1^-/- apoE double-knockout mice exhibit reduced macrophage recruitment into atherosclerotic lesions.^38,39 However, our identification of fractal-kine as a chemoattractant for SMCs suggests that this unusual CX₃C chemokine merits further investigation in human atherosclerosis and other forms of vascular remodeling, including restenosis and arteriosclerosis.

	Acknowledgments

 
This work was supported by a Wellcome Trust Cardiovascular Research Initiative Fellowship to Dr Lucas, a Wellcome Trust International fellowship to Dr Guzik, and a British Heart Foundation project grant to Drs Channon and Greaves.

	Footnotes

 
*Drs Lucas and Bursill contributed equally to this work.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–126.[Free Full Text]

2. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001; 104: 503–516.[CrossRef][Medline] [Order article via Infotrieve]

3. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135–1143.[Abstract/Free Full Text]

4. Greaves DR, Channon KM. Inflammation and immune responses in atherosclerosis. Trends Immunol. 2002; 23: 535–541.[CrossRef][Medline] [Order article via Infotrieve]

5. Greaves DR, Gough PJ, Gordon S. Recent progress in defining the role of scavenger receptors in lipid transport, atherosclerosis and host defence. Curr Opin Lipidol. 1998; 9: 425–432.[CrossRef][Medline] [Order article via Infotrieve]

6. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001; 104: 365–372.[Free Full Text]

7. Becker AE, de Boer OJ, van Der Wal AC. The role of inflammation and infection in coronary artery disease. Annu Rev Med. 2001; 52: 289–297.[CrossRef][Medline] [Order article via Infotrieve]

8. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med. 1998; 338: 436–445.[Free Full Text]

9. Baggiolini M. Chemokines in pathology and medicine. J Intern Med. 2001; 250: 91–104.[CrossRef][Medline] [Order article via Infotrieve]

10. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol. 2002; 2: 106–115.[CrossRef][Medline] [Order article via Infotrieve]

11. Boring L, Gosling J, Cleary M, et al. Decreased lesion formation in CCR2^-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394: 894–897.[CrossRef][Medline] [Order article via Infotrieve]

12. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2: 275–281.[CrossRef][Medline] [Order article via Infotrieve]

13. Roque M, Kim WJ, Gazdoin M, et al. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol. 2002; 22: 554–559.[Abstract/Free Full Text]

14. Egashira K, Zhao Q, Kataoka C, et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res. 2002; 90: 1167–1172.[Abstract/Free Full Text]

15. Wilcox JN, Nelken NA, Coughlin SR, et al. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb. 1994; 1 (suppl 1): S10–S13.[Medline] [Order article via Infotrieve]

16. Haley KJ, Lilly CM, Yang JH, et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation. 2000; 102: 2185–2189.[Abstract/Free Full Text]

17. Greaves DR, Hakkinen T, Lucas AD, et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001; 21: 923–929.[Abstract/Free Full Text]

18. Huo Y, Weber C, Forlow SB, et al. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest. 2001; 108: 1307–1314.[CrossRef][Medline] [Order article via Infotrieve]

19. Boisvert WA, Santiago R, Curtiss LK, et al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest. 1998; 101: 353–363.[Medline] [Order article via Infotrieve]

20. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997; 385: 640–644.[CrossRef][Medline] [Order article via Infotrieve]

21. Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A. 1998; 95: 10896–10901.[Abstract/Free Full Text]

22. Lucas AD, Chadwick N, Warren BF, et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol. 2001; 158: 855–866.[Abstract/Free Full Text]

23. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997; 91: 521–530.[CrossRef][Medline] [Order article via Infotrieve]

24. Fong AM, Robinson LA, Steeber DA, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998; 188: 1413–1419.[Abstract/Free Full Text]

25. Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction: rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem. 1999; 274: 10053–10058.[Abstract/Free Full Text]

26. Jung S, Aliberti J, Graemmel P, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000; 20: 4106–4114.[Abstract/Free Full Text]

27. Soriano SG, Amaravadi LS, Wang YF, et al. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol. 2002; 125: 59–65.[CrossRef][Medline] [Order article via Infotrieve]

28. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001; 97: 1925–1928.[Abstract/Free Full Text]

29. McDermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 2001; 89: 401–407.[Abstract/Free Full Text]

30. Alexander RW. Cytokine receptor CX3CR-1 and fractalkine: new factors in the atherosclerosis drama? Circ Res. 2001; 89: 376–377.[Free Full Text]

31. Boyle JJ, Bowyer DE, Weissberg PL, et al. Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Arterioscler Thromb Vasc Biol. 2001; 21: 1402–1407.[Abstract/Free Full Text]

32. Bursill CA, Cai S, Channon KM, et al. Adenoviral-mediated delivery of a viral chemokine binding protein blocks CC-chemokine activity in vitro and in vivo. Immunobiology. 2003; 207: 187–196.[CrossRef][Medline] [Order article via Infotrieve]

33. Ludwig A, Berkhout T, Moores K, et al. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol. 2002; 168: 604–612.[Abstract/Free Full Text]

34. Chandrasekar B, Mummidi S, Perla RP, et al. Fractalkine (CX3CL1) stimulated by NF-kappaB-dependent inflammatory signals induces aortic smooth muscle cells proliferation through an autocrine pathway. Biochem J. 2003; 373 (pt 2): 547–558.[CrossRef][Medline] [Order article via Infotrieve]

35. McDermott DH, Fong AM, Yang Q, et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003; 111: 1241–1250.[CrossRef][Medline] [Order article via Infotrieve]

36. Streblow DN, Soderberg-Naucler C, Vieira J, et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell. 1999; 99: 511–520.[CrossRef][Medline] [Order article via Infotrieve]

37. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997; 350: 430–436.[CrossRef][Medline] [Order article via Infotrieve]

38. Combadiere C, Potteaux S, Gao JL, et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003; 107: 1009–1016.[Abstract/Free Full Text]

39. Lesnik P, Haskell CA, Charo IF, Decreased atherosclerosis in CX3CR1^-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003; 111: 333–340.[CrossRef][Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				M. J. Koziolek, G.-A. Muller, A. Zapf, D. Patschan, H. Schmid, C. D. Cohen, S. Koschnick, R. Vasko, C. Bramlage, and F. Strutz Role of CX3C-chemokine CX3C-L/fractalkine expression in a model of slowly progressive renal failure Nephrol. Dial. Transplant., November 24, 2009; (2009) gfp602v1. [Abstract] [Full Text] [PDF]

				G. E. White, T. C.C. Tan, A. E. John, C. Whatling, W. L. McPheat, and D. R. Greaves Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling Cardiovasc Res, November 12, 2009; (2009) cvp341v2. [Abstract] [Full Text] [PDF]

				S. Debette, S. Bevan, J.-F. Dartigues, M. Sitzer, M. Lorenz, P. Ducimetiere, P. Amouyel, and H. S. Markus Fractalkine Receptor/Ligand Genetic Variants and Carotid Intima-Media Thickness Stroke, June 1, 2009; 40(6): 2212 - 2214. [Abstract] [Full Text] [PDF]

				G. Pacheco-Rodriguez, F. Kumaki, W. K. Steagall, Y. Zhang, Y. Ikeda, J.-P. Lin, E. M. Billings, and J. Moss Chemokine-Enhanced Chemotaxis of Lymphangioleiomyomatosis Cells with Mutations in the Tumor Suppressor TSC2 Gene J. Immunol., February 1, 2009; 182(3): 1270 - 1277. [Abstract] [Full Text] [PDF]

				J. Ryu, C.-W. Lee, K.-H. Hong, J.-A. Shin, S.-H. Lim, C.-S. Park, J. Shim, K. B. Nam, K.-J. Choi, Y.-H. Kim, et al. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia Cardiovasc Res, May 1, 2008; 78(2): 333 - 340. [Abstract] [Full Text] [PDF]

				H. Loppnow, K. Werdan, and M. Buerke Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms Innate Immunity, April 1, 2008; 14(2): 63 - 87. [Abstract] [PDF]

				W. L. Jamieson, S. Shimizu, J. A. D'Ambrosio, O. Meucci, and A. Fatatis CX3CR1 Is Expressed by Prostate Epithelial Cells and Androgens Regulate the Levels of CX3CL1/Fractalkine in the Bone Marrow: Potential Role in Prostate Cancer Bone Tropism Cancer Res., March 15, 2008; 68(6): 1715 - 1722. [Abstract] [Full Text] [PDF]

				Y. Ishida, J.-L. Gao, and P. M. Murphy Chemokine Receptor CX3CR1 Mediates Skin Wound Healing by Promoting Macrophage and Fibroblast Accumulation and Function J. Immunol., January 1, 2008; 180(1): 569 - 579. [Abstract] [Full Text] [PDF]

				X. P. Yang, S. Mattagajasingh, S. Su, G. Chen, Z. Cai, K. Fox-Talbot, K. Irani, and L. C. Becker Fractalkine Upregulates Intercellular Adhesion Molecule-1 in Endothelial Cells Through CX3CR1 and the Jak Stat5 Pathway Circ. Res., November 9, 2007; 101(10): 1001 - 1008. [Abstract] [Full Text] [PDF]

				C. Schulz, A. Schafer, M. Stolla, S. Kerstan, M. Lorenz, M.-L. von Bruhl, M. Schiemann, J. Bauersachs, T. Gloe, D. H. Busch, et al. Chemokine Fractalkine Mediates Leukocyte Recruitment to Inflammatory Endothelial Cells in Flowing Whole Blood: A Critical Role for P-Selectin Expressed on Activated Platelets Circulation, August 14, 2007; 116(7): 764 - 773. [Abstract] [Full Text] [PDF]

				J. Barlic and P. M. Murphy Chemokine regulation of atherosclerosis J. Leukoc. Biol., August 1, 2007; 82(2): 226 - 236. [Abstract] [Full Text] [PDF]

				C Hamid, K Norgate, D P D'Cruz, M A Khamashta, M Arno, J D Pearson, G Frampton, and J J Murphy Anti-{beta}2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome Ann Rheum Dis, August 1, 2007; 66(8): 1000 - 1007. [Abstract] [Full Text] [PDF]

				J. Barlic, Y. Zhang, and P. M. Murphy Atherogenic Lipids Induce Adhesion of Human Coronary Artery Smooth Muscle Cells to Macrophages by Up-regulating Chemokine CX3CL1 on Smooth Muscle Cells in a TNF{alpha}-NF{kappa}B-dependent Manner J. Biol. Chem., June 29, 2007; 282(26): 19167 - 19176. [Abstract] [Full Text] [PDF]

				D. Xing, W. Feng, A. P. Miller, N. M. Weathington, Y.-F. Chen, L. Novak, J. E. Blalock, and S. Oparil Estrogen modulates TNF-{alpha}-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2607 - H2612. [Abstract] [Full Text] [PDF]

				F. Perros, P. Dorfmuller, R. Souza, I. Durand-Gasselin, V. Godot, F. Capel, S. Adnot, S. Eddahibi, M. Mazmanian, E. Fadel, et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension Eur. Respir. J., May 1, 2007; 29(5): 937 - 943. [Abstract] [Full Text] [PDF]

				D. Segers, F. Helderman, C. Cheng, L. C.A. van Damme, D. Tempel, E. Boersma, P. W. Serruys, R. de Crom, A. F.W. van der Steen, P. Holvoet, et al. Gelatinolytic Activity in Atherosclerotic Plaques Is Highly Localized and Is Associated With Both Macrophages and Smooth Muscle Cells In Vivo Circulation, February 6, 2007; 115(5): 609 - 616. [Abstract] [Full Text] [PDF]

				A. Schafer, C. Schulz, D. Fraccarollo, P. Tas, M. Leutke, M. Eigenthaler, S. Seidl, P. Heider, G. Ertl, S. Massberg, et al. The CX3C Chemokine Fractalkine Induces Vascular Dysfunction by Generation of Superoxide Anions Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 55 - 62. [Abstract] [Full Text] [PDF]

				P. Liu, S. Patil, M. Rojas, A. M. Fong, S. S. Smyth, and D. D. Patel CX3CR1 Deficiency Confers Protection From Intimal Hyperplasia After Arterial Injury Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2056 - 2062. [Abstract] [Full Text] [PDF]

				J. Barlic, Y. Zhang, J. F. Foley, and P. M. Murphy Oxidized Lipid-Driven Chemokine Receptor Switch, CCR2 to CX3CR1, Mediates Adhesion of Human Macrophages to Coronary Artery Smooth Muscle Cells Through a Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Pathway Circulation, August 22, 2006; 114(8): 807 - 819. [Abstract] [Full Text] [PDF]

				G. D. Norata, K. Garlaschelli, M. Ongari, S. Raselli, L. Grigore, and A. L. Catapano Effects of Fractalkine Receptor Variants on Common Carotid Artery Intima-Media Thickness Stroke, June 1, 2006; 37(6): 1558 - 1561. [Abstract] [Full Text] [PDF]

				M. E. DeVries, A. A. Kelvin, L. Xu, L. Ran, J. Robinson, and D. J. Kelvin Defining the Origins and Evolution of the Chemokine/Chemokine Receptor System J. Immunol., January 1, 2006; 176(1): 401 - 415. [Abstract] [Full Text] [PDF]

				J. K. Damas, A. Boullier, T. Waehre, C. Smith, W. J. Sandberg, S. Green, P. Aukrust, and O. Quehenberger Expression of Fractalkine (CX3CL1) and its Receptor, CX3CR1, Is Elevated in Coronary Artery Disease and Is Reduced During Statin Therapy Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2567 - 2572. [Abstract] [Full Text] [PDF]

				O. Quehenberger Thematic Review Series: The Immune System and Atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis J. Lipid Res., August 1, 2005; 46(8): 1582 - 1590. [Abstract] [Full Text] [PDF]

				E. A. Heller, E. Liu, A. M. Tager, S. Sinha, J. D. Roberts, S. L. Koehn, P. Libby, E. R. Aikawa, J. Q. Chen, P. Huang, et al. Inhibition of Atherogenesis in BLT1-Deficient Mice Reveals a Role for LTB4 and BLT1 in Smooth Muscle Cell Recruitment Circulation, July 26, 2005; 112(4): 578 - 586. [Abstract] [Full Text] [PDF]

				E. W. Raines and N. Ferri Thematic Review Series: The Immune System and Atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease J. Lipid Res., June 1, 2005; 46(6): 1081 - 1092. [Abstract] [Full Text] [PDF]

				E. Lavergne, J. Labreuche, M. Daoudi, P. Debre, F. Cambien, P. Deterre, P. Amarenco, C. Combadiere, and on Behalf of the GENIC Investigators Adverse Associations Between CX3CR1 Polymorphisms and Risk of Cardiovascular or Cerebrovascular Disease Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 847 - 853. [Abstract] [Full Text] [PDF]

				D. Teupser, S. Pavlides, M. Tan, J.-C. Gutierrez-Ramos, R. Kolbeck, and J. L. Breslow Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root PNAS, December 21, 2004; 101(51): 17795 - 17800. [Abstract] [Full Text] [PDF]

				C. Weber, A. Schober, and A. Zernecke Chemokines: Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 1997 - 2008. [Abstract] [Full Text] [PDF]

				C. A. Bursill, R. P. Choudhury, Z. Ali, D. R. Greaves, and K. M. Channon Broad-Spectrum CC-Chemokine Blockade by Gene Transfer Inhibits Macrophage Recruitment and Atherosclerotic Plaque Formation in Apolipoprotein E-Knockout Mice Circulation, October 19, 2004; 110(16): 2460 - 2466. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 108/20/2498    most recent 01.CIR.0000097119.57756.EFv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lucas, A. D. Articles by Greaves, D. R. Search for Related Content PubMed PubMed Citation Articles by Lucas, A. D. Articles by Greaves, D. R. Related Collections Pathophysiology Mechanism of atherosclerosis/growth factors